STOCK TITAN
  1. Home
  2. Sec-filings
  3. PSTV
  4. [Form 4/A] PLUS THERAPEUTICS, INC. Amended Insider Trading Activity

PSTV CEO Awarded 1,916,168 RSUs; Amendment Clarifies Vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

Marc H. Hedrick, identified as Director and Chief Executive Officer of Plus Therapeutics, Inc. (PSTV), reported equity awards dated 08/13/2025 in an amended Form 4/A. The filing shows an award of 5,748,506 stock options with an exercise price of $0.5744 and an award of 1,916,168 Restricted Stock Units (RSUs). The RSUs vest over twelve quarters, beginning with the quarter ended September 30, 2025, and convert one-for-one into common shares on vesting. The amendment corrects previously disclosed vesting terms for the RSUs. The Form 4/A is signed by an attorney-in-fact on behalf of the reporting person on 10/03/2025.

Positive

  • None.

Negative

  • None.

Insights

Large executive equity awards disclosed and RSU vesting correction.

The filing documents a grant of 5,748,506 stock options at an exercise price of $0.5744 and 1,916,168 RSUs to Marc H. Hedrick on 08/13/2025. The Form 4/A amends an earlier filing to correct the RSU vesting schedule.

This matters for governance transparency: the corrected disclosure clarifies the timing when RSUs convert to shares and completes the issuer's Section 16 reporting obligations. The RSUs vest in substantially equal 1/12th increments beginning the quarter ended September 30, 2025.

Insider HEDRICK MARC H
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 5,748,506 $0.00 --
Grant/Award Restricted Stock Units 1,916,168 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 5,748,506 shares (Direct); Restricted Stock Units — 1,916,168 shares (Direct)
Footnotes (1)
  1. The options vest over four years in equal 1/48th increments on each monthly anniversary of the issuance. This amendment is being filed to correct a Form 4 filed on August 15, 2025, which inadvertently disclosed the incorrect vesting terms of the Restricted Stock Units ("RSUs"). The RSUs awarded on August 13, 2025 vest over twelve quarters, vesting in substantially equal 1/12th increments beginning with the quarter ended September 30, 2025. The RSUs convert into shares of Common Stock upon vesting on a one for one basis.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
HEDRICK MARC H
(Last) (First) (Middle)
C/O PLUS THERAPEUTICS INC.
4200 MARATHON BOULEVARD, SUITE 200
(Street)
AUSTIN TX 78756
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
08/15/2025 		6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $0.5744 08/13/2025 A 5,748,506 (1) 08/12/2035 Common Stock 5,748,506 $0.00 5,748,506 D
Restricted Stock Units (2) 08/13/2025 A 1,916,168 (2) (2) Common Stock 1,916,168 $0.00 1,916,168 D
Explanation of Responses:
1. The options vest over four years in equal 1/48th increments on each monthly anniversary of the issuance.
2. This amendment is being filed to correct a Form 4 filed on August 15, 2025, which inadvertently disclosed the incorrect vesting terms of the Restricted Stock Units ("RSUs"). The RSUs awarded on August 13, 2025 vest over twelve quarters, vesting in substantially equal 1/12th increments beginning with the quarter ended September 30, 2025. The RSUs convert into shares of Common Stock upon vesting on a one for one basis.
/s/ Andrew Sims, attorney-in-fact 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Marc H. Hedrick report on the Form 4/A for PSTV?

The Form 4/A reports grants dated 08/13/2025 of 5,748,506 stock options at $0.5744 and 1,916,168 RSUs to Marc H. Hedrick.

How do the RSUs for PSTV awarded to the CEO vest?

The RSUs vest over twelve quarters in substantially equal 1/12th increments beginning with the quarter ended September 30, 2025 and convert one-for-one into common shares on vesting.

Why was an amended Form 4 (4/A) filed for PSTV?

The amendment corrects an earlier Form 4 that inadvertently disclosed incorrect vesting terms for the RSUs awarded on 08/13/2025.

Who signed the amended Form 4/A for PSTV?

The Form 4/A is signed by /s/ Andrew Sims, attorney-in-fact on 10/03/2025.

What is the exercise price and reported exercisability detail for the options?

The reported exercise price is $0.5744 for 5,748,506 options; the filing lists a date related to exercise detail of 08/12/2035 as shown in the table.